Ark Invest Trims AMD Again While Pivoting to Tempus AI

Benzinga reported Wednesday that Ark Invest CEO Cathie Wood continued offloading Advanced Micro Devices shares while simultaneously building a position in Tempus AI, a healthcare artificial-intelligence company. The dual move signals a notable rotation within Ark’s flagship growth funds.

Ark Unloads More AMD After a $16 Million Tuesday Sale

Wood’s Cathie Wood AMD sell-off now spans two consecutive sessions. On Tuesday, Ark disposed of approximately $16 million in AMD stock as the chipmaker’s share price surged on strong earnings. Wednesday brought a follow-on sale of around 18,900 shares from the ARK Innovation ETF, worth roughly $8 million at AMD’s closing price near $421.

AMD has recently posted record highs, supported by first-quarter earnings and second-quarter guidance that both cleared analyst expectations. The company has also positioned itself to benefit from expanding server CPU demand tied to agentic AI workloads. Despite those tailwinds, Ark appears content locking in gains at elevated levels.

Why Ark Is Buying Tempus AI

On the buy side, Ark’s ARKG and ARKK funds together acquired roughly 145,000 Tempus AI shares. At a closing price near $53.50, the combined transaction value reached approximately $7.8 million.

Tempus AI recently disclosed a 36% jump in first-quarter revenue, with its oncology diagnostics unit leading the charge. The company’s quarterly sales of roughly $348 million edged past consensus forecasts. Its data and applications segment posted particularly strong growth, climbing more than 40% year over year. Tempus also raised its full-year revenue outlook despite reporting a wider net loss.

Background on Ark’s Trading Strategy

Ark has a long-standing practice of publishing its daily trades publicly, giving markets unusual transparency into Wood’s conviction shifts. The firm tends to trim positions after sharp price appreciation and redeploy capital into names with higher perceived upside.

AMD has been one of Ark’s more tactical holdings, with the fund buying into weakness and selling into strength repeatedly over the past year. Tempus AI, by contrast, represents a newer focus area where Ark is building scale incrementally.

Ark also sold shares in gene-editing firm Twist Bioscience across both ARKG and ARKK on Wednesday. Separately, the firm purchased roughly 28,000 shares of Intellia Therapeutics, suggesting continued rebalancing within its genomics sleeve.

AMD’s momentum ranking sits in the 96th percentile by Benzinga’s internal stock scoring model. Its value score, however, registers near the bottom of the range, a dynamic that may partly explain Ark’s willingness to reduce exposure at current prices.

Read Next: What Is Agentic AI and Why Are Chipmakers Betting Big on It